Russia to begin production of epilepsy drug ethosuximide

26 January 2022

Russia plans to begin the production of a scarce drug based on ethosuximide for the treatment of epilepsy, according to recent statements by some of local analysts in the field of pharmaceutics and Russian media, reports The Pharma Letter’s local correspondent.

It is planned, such production will be launched on the basis of the local PIQ-Pharma Group, which has already initiated the procedure for registering the drug under the Epilexid brand. Ethosuxide was originated and marketed by Pfizer (NYSE: PFE) under the trade name Zarontin.

The drug in the form of a syrup will be produced from an active ingredient imported from the Netherlands. The company plans to start deliveries in mid-2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK